Compound
D1096 | sodium warfarin
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 38.57±12.82 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 35.48 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 35.48±0.00 | rat | hepatocytes | MMP assay | decrease | IC50 | 163 | |
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
  |
Danger |
Aggregated GHS information provided by 104 companies from 11 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral] H310 (50%): Fatal in contact with skin [Danger Acute toxicity, dermal] H330 (50%): Fatal if inhaled [Danger Acute toxicity, inhalation] H360 (100%): May damage fertility or the unborn child [Danger Reproductive toxicity] H372 (49.04%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P201, P202, P260, P262, P264, P270, P271, P280, P281, P284, P301+P310, P302+P350, P304+P340, P308+P313, P310, P314, P320, P321, P322, P330, P361, P363, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
|---|---|---|---|---|---|
| chicken | LD50 | intravenous | 200mg/kg (200mg/kg) | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 42, Pg. 379, 1953. | |
| rat | LD50 | oral | 8700ug/kg (8.7mg/kg) | blood: hemorrhage | Pharmacological Research Communications. Vol. 10, Pg. 445, 1978. |
| rabbit | LD50 | oral | 800mg/kg (800mg/kg) | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 42, Pg. 379, 1953. | |
| dog | LD50 | intravenous | 200mg/kg (200mg/kg) | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 42, Pg. 379, 1953. | |
| women | TDLo | oral | 300ug/kg/2D (0.3mg/kg) | skin and appendages (skin): "dermatitis, other: after systemic exposure" | Archives of Dermatology. Vol. 116, Pg. 444, 1980. |
| rabbit | LD50 | intravenous | 100mg/kg (100mg/kg) | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 42, Pg. 379, 1953. | |
| dog | LD50 | oral | 200mg/kg (200mg/kg) | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 42, Pg. 379, 1953. | |
| rat | LD50 | intravenous | 25mg/kg (25mg/kg) | "Handbook of Analytical Toxicology," Sunshine, I., ed., Cleveland, OH, Chemical Rubber Co., 1969Vol. -, Pg. 123, 1969. | |
| mouse | LD50 | intravenous | 160mg/kg (160mg/kg) | "Handbook of Analytical Toxicology," Sunshine, I., ed., Cleveland, OH, Chemical Rubber Co., 1969Vol. -, Pg. 123, 1969. | |
| child | TDLo | oral | 4mg/kg (4mg/kg) | blood: changes in cell count (unspecified) | American Journal of Diseases of Children. Vol. 147, Pg. 609, 1993. |
| guinea pig | LD50 | oral | 182mg/kg (182mg/kg) | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 42, Pg. 379, 1953. | |
| mouse | LD50 | oral | 374mg/kg (374mg/kg) | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 42, Pg. 379, 1953. | |
| guinea pig | LDLo | intravenous | 543mg/kg (543mg/kg) | Therapie. Vol. 18, Pg. 921, 1963. | |
| (+-)-Warfarin sodium | 129-06-6 | 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-, sodium salt |
| 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-, sodium salt (1:1) | 2H-1-Benzopyran-2-one,4-hydroxy-3-[(1S)-3-oxo-1-phenylbutyl]-, sodium salt (9CI) | 3-(3-Oxo-1-phenylbutyl)-4-sodiooxy-2H-1-benzopyran-2-one |
| 3-(alpha-Acetonylbenzyl)-4-hydroxycoumarin Sodiuim Salt | 3-(alpha-Acetonylbenzyl)-4-hydroxycoumarin sodium salt | 4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin Sodium Salt |
| 5543-79-3 | 67430-45-9 | A805899 |
| AB0013224 | AB1009293 | AC-19972 |
| AC-8078 | AKOS015951251 | AKOS015955387 |
| API0004610 | AX8156592 | Aldocumar |
| Athrombin | Athrombine-K sodium | BCP20702 |
| BDBM50248297 | C-20012 | C19H15NaO4 |
| C19H15O4.Na | CAS-129-06-6 | CC-35635 |
| CHEMBL1200879 | CPD000058849 | CS-W019743 |
| CTK5A3600 | Caswell No. 903A | Coumadan Sodico |
| Coumadin (TN) | Coumadin sodium | Coumadin sodium|||4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-Benzopyran-2-one, sodium salt (1:1); |
| Coumadine | Coumafene sodium | Coumarin, 3-(alpha-acetonylbenzyl)-4-hydroxy-, sodium salt |
| D00564 | DSSTox_CID_15010 | DSSTox_GSID_35010 |
| DSSTox_RID_79236 | DTXSID7035010 | Dicusat |
| EINECS 204-929-4 | EINECS 226-909-4 | EPA Pesticide Chemical Code 086003 |
| H742 | HMS2233P10 | HMS3259G13 |
| HMS3369M10 | J-005647 | J10262 |
| Jantoven | Jantoven (TN) | KYITYFHKDODNCQ-UHFFFAOYSA-M |
| LS-55086 | MCULE-2794487450 | MLS001074341 |
| Marevam | Marevan | NC00490 |
| NCGC00255556-01 | Orfarin | Q27263296 |
| Ratsul soluble | SAM002548943 | SAM002554882 |
| SCHEMBL7826 | SMR000058849 | ST24031985 |
| Simarc | Sodium 2-oxo-3-(3-oxo-1-phenylbutyl)-2H-chromen-4-olate | Sodium coumadin |
| Sodium warfarin | Sodium warfarin;WARF42 sodium | Sodium, ((3-(alpha-acetonylbenzyl)-2-oxo-2H-1-benzopyran-4-yl)oxy)- |
| Tintorane | Tox21_301545 | UniWarfin |
| Varfine | W0005 | Waran |
| Warcoumin | Warfarin sodium | Warfarin sodium (USP) |
| Warfarin sodium (contains Isopropyl Alcohol) | Warfarin sodium [USAN] | Warfarin sodium [USP] |
| Warfarin sodium clathrate | Warfarin sodium salt | Warfarin, sodium deriv |
| Warfarin, sodium deriv. | Warfarin, sodium salt | Warfilone |
| Zoocoumarin sodium salt | sodium 2-oxidanylidene-3-(3-oxidanylidene-1-phenyl-butyl)chromen-4-olate | sodium 2-oxo-3-(3-oxo-1-phenylbutyl)-1-benzopyran-4-olate |
| warfarin-sodium |